Studies from our laboratory on cancer cell lines demonstrated that APLP2 associates with the major histocompatibility complex (MHC) class I molecule, which presents tumor antigens and thereby activates T cell killing of malignant cells (17–20). Here, APLP2 is linked to neoplasm.